Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
Study Goal
The researchers aimed to compare the efficacy of once-weekly subcutaneous semaglutide 2.4 mg versus placebo for weight loss and improvements in cardiometabolic parameters in people with obesity.
Results Summary
Semaglutide led to greater reductions in body weight, waist circumference, BMI, systolic and diastolic blood pressure, and positive changes in HbA1c compared to placebo across multiple trials.
Population
People with overweight or obesity.
Effective Dosage
Once-weekly subcutaneous semaglutide 2.4 mg.
Duration
Not specified in the abstract.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
once-weekly subcutaneous semaglutide 2.4 mg | decrease | body weight | people with obesity | - | greater reductions from baseline versus placebo | #1 |
once-weekly subcutaneous semaglutide 2.4 mg | decrease | waist circumference | people with obesity | - | greater reductions from baseline versus placebo | #2 |
once-weekly subcutaneous semaglutide 2.4 mg | decrease | body mass index | people with obesity | - | greater reductions from baseline versus placebo | #3 |
once-weekly subcutaneous semaglutide 2.4 mg | decrease | systolic blood pressure (SBP) | people with obesity | - | greater reductions from baseline versus placebo | #4 |
once-weekly subcutaneous semaglutide 2.4 mg | decrease | diastolic blood pressure | people with obesity | - | greater reductions from baseline versus placebo | #5 |
once-weekly subcutaneous semaglutide 2.4 mg | decrease | glycated hemoglobin (HbA1c) | people with obesity | - | positive changes | #6 |
People with overweight or obesity often suffer from associated cardiometabolic diseases and comorbidities. Current therapies for obesity include lifestyle intervention, bariatric surgery, and pharmacotherapy. The magnitude of weight loss achieved with these therapies can determine the level of improvement in various comorbidities. Once-weekly subcutaneous semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist recently approved by the US Food and Drug Administration for the treatment of obesity. This article reviews data from the global phase 3 Semaglutide Treatment Effect in People with obesity (STEP) program, comparing the efficacy of once-weekly subcutaneous semaglutide 2.4 mg versus placebo for weight loss and improvements in cardiometabolic parameters across the STEP 1 to 5 trials. In STEP 1 to 3 and STEP 5, semaglutide led to greater reductions from baseline versus placebo in body weight, waist circumference, body mass index, systolic blood pressure (SBP), and diastolic blood pressure, as well as positive changes in glycated hemoglobin (HbA